3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Carcinoma, Renal Cell
65
Neoplasms
10
Neoplasm Metastasis
9
Kidney Neoplasms
7
Prostatic Neoplasms
5
Urinary Bladder Neoplasms
4
Sarcoma
4
Clear-cell metastatic renal cell carcinoma
4
Breast Neoplasms
4
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Melanoma
2
Financial Stress
2
Carcinoma, Non-Small-Cell Lung
2
Wilms Tumor
1
Uterine Cervical Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Patient Preference
1
Pathologic Complete Response
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Osteosarcoma
1
Oncocytoma, renal
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms, Germ Cell and Embryonal
1
Lung Neoplasms
1
Liver Neoplasms
1
Interventions
pembrolizumab
18
Nivolumab
6
Radiotherapy
5
Paclitaxel
5
Trastuzumab
4
Specimen Handling
4
Ipilimumab
4
tisotumab vedotin
3
temsirolimus
3
olaparib
3
lenvatinib
3
X-Rays
3
Taxes
3
Surveys and Questionnaires
3
Early Intervention, Educational
3
Cyclophosphamide
3
Carboplatin
3
Biopsy
3
spartalizumab
2
sargramostim
2
rucaparib
2
palbociclib
2
fludarabine
2
epacadostat
2
enzalutamide
2
durvalumab
2
cabozantinib
2
atezolizumab
2
aflibercept
2
Vinorelbine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
pazopanib
×
Genitourinary
×
Clear all
NCT05949424
2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4
Unknown
30 enrolled